OIM
PACB icon

Oracle Investment Management’s Pacific Biosciences PACB Stock Holding History

Oracle Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-67,000
Closed -$126K – 36
2021
Q4 		$126K Buy
+67,000
New +$1.62M 0.02% 30
2021
Q2 		– Sell
-100,000
Closed -$505K – 30
2021
Q1 		$505K Buy
+100,000
New +$3.5M 0.08% 24

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oracle Investment Management's PACB Position: Q1 2025 in Review

Oracle Investment Management sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 279,638 shares — an estimated $512K sold.

Oracle Investment Management first reported a position in PACB in Q2 2013 and held it in 47 quarters. The position peaked at $50.8M in Q3 2018. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

  • Oracle Investment Management reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
  • Oracle Investment Management sold 279,638 Pacific Biosciences shares in Q1 2025, an estimated $512K.
  • Oracle Investment Management first reported a position in Pacific Biosciences in Q2 2013 and held it in 47 quarters.
  • Oracle Investment Management's Pacific Biosciences position peaked at $50.8M in Q3 2018.
  • 225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Oracle Investment Management's 13F filing for Q1 2025, filed 15 May 2025.